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The protective role of specific antibodies against Paracoccidioides brasiliensis is controversial. In the present
study, we analyzed the effects of monoclonal antibodies on the major diagnostic antigen (gp43) using in vitro
and in vivo P. brasiliensis infection models. The passive administration of some monoclonal antibodies (MAbs)
before and after intratracheal or intravenous infections led to a reduced fungal burden and decreased
pulmonary inflammation. The protection mediated by MAb 3E, the most efficient MAb in the reduction of
fungal burden, was associated with the enhanced phagocytosis of P. brasiliensis yeast cells by J774.16, MH-S,
or primary macrophages. The ingestion of opsonized yeast cells led to an increase in NO production by
macrophages. Passive immunization with MAb 3E induced enhanced levels of gamma interferon in the lungs
of infected mice. The reactivity of MAb 3E against a panel of gp43-derived peptides suggested that the sequence
NHVRIPIGWAV contains the binding epitope. The present work shows that some but not all MAbs against
gp43 can reduce the fungal burden and identifies a new peptide candidate for vaccine development.
Paracoccidioides brasiliensis is a thermally dimorphic fungus
that is the etiological agent of paracoccidioidomycosis (PCM),
the most prevalent systemic mycosis in Latin America that is
endemic in areas of Brazil, Argentina, Colombia, and Vene-
zuela. The impact of the disease is demonstrated by Coutinho
et al. (14), who reported that 3,181 lethal cases of PCM oc-
curred in the 1980 to 1995 period in Brazil. The acute and
subacute forms of PCM affect both genders and primarily
involve the reticuloendothelial/lymphatic system. The chronic
form affects mainly adult males with predominant pulmonary
and/or mucocutaneous involvement (20). The activation of the
immune cellular response is the primary effective mechanism
to control experimental and human PCM (4, 25). A correlation
has been found between the severity of the disease and an
impaired delayed-type hypersensitivity response (30).
Antifungal chemotherapy is required for PCM treatment,
though even after prolonged administration, there is no assur-
ance of the complete destruction of the fungus. The period of
treatment depends on the drug used and disease severity. Stan-
dard drugs include sulfonamides, amphotericin B, and azoles
(44).
gp43, first described by Puccia et al. (35), is the major diag-
nostic antigen of P. brasiliensis used in a variety of serological
tests (16, 50). Antibody titers to gp43 have been used to mon-
itor the response to treatment in patients (6). gp43 has also
proven to be immunodominant in a crude antigenic prepara-
tion, eliciting delayed hypersensitivity reactions in guinea pigs
(40) and humans (42), which indicated the presence of
T-CD4-reacting epitopes.
The gp43 gene has been cloned and sequenced (13). It
encodes a polypeptide of 416 amino acids (Mr, 45,947) with a
leader peptide of 35 residues; the mature protein has a single
high-mannose N-glycosylated chain (1). The H-2d-restricted
T-cell epitope has been mapped to a 15-mer peptide called P10
(48). Different 12-mer sequences, all containing the hexapep-
tide HTLAIR, induce the proliferation of lymph node cells
from mice sensitized to gp43 or infected with P. brasiliensis.
Lymphoproliferation induced by either P10 or gp43 involves
CD4 T-helper lymphocytes producing interleukin-2 (IL-2)
and gamma interferon (IFN-). The immunization of mice
with either gp43 or P10 in complete Freund’s adjuvant signif-
icantly protected them from intratracheal (i.t.) infection with
virulent yeasts of P. brasiliensis. After 3 months of infection,
the lung CFU were 200-fold fewer than in the untreated
control mice.
The role of antibody-mediated immunity in host resistance
to P. brasiliensis is less certain (10). In several systems, how-
ever, there is considerable evidence that the administration of
monoclonal antibodies (MAbs) can modify the course of dis-
ease in mice infected with fungi such as Cryptococcus neofor-
mans (28), Candida albicans (15, 24), Histoplasma capsulatum
(31), Pneumocystis spp. (51), Fonsecaea pedrosoi (2), Aspergillus
spp. (12), and, more recently, P. brasiliensis (17).
The mechanisms of antibody action in combatting an infec-
tious disease include antigen neutralization, cooperative effects
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with cellular immunity by the enhancement of phagocytosis or
mediating-cell cytotoxicity, complement activation, growth in-
hibition, adherence, and biofilm or direct antimicrobial effects
(reviewed in reference 11). With C. neoformans, it is clear that
antibody-mediated immunity can be decisive for host defense.
The mechanisms involved are complex and dependent on sev-
eral parameters, such as antibody isotype (26), T-cell function
(53), C. neoformans strain (29), antibody quantity (49), expres-
sion of inducible NO synthase (39), Fc region, and comple-
ment activation (43).
The control of PCM is classically associated with a vigorous
Th1 response and granuloma formation. There is evidence,
however, that antibody-mediated immunity can contribute to
infection clearance. In the present study, a panel of MAbs
against gp43 was utilized for evaluating the effect of passive
immunization in mice intravenously (i.v.) or i.t. infected with a
virulent strain of P. brasiliensis.
MATERIALS AND METHODS
Animals. BALB/c mice (6- to 8-week-old males) were bred at the University of
Sa˜o Paulo, Sa˜o Paulo, Brazil, animal facility under specific pathogen-free con-
ditions. The procedures involving animals and their care were conducted accord-
ing to the local ethics committee and international rules.
Fungal strain. Virulent P. brasiliensis Pb18 yeast cells were maintained by
weekly passage on solid Sabouraud medium at 37°C and were used after 7 to 10
days of growth. Before the experimental infection, the fungus was grown in
modified McVeigh-Morton medium at 37°C for 5 to 7 days (38). The fungal cells
were washed in phosphate-buffered saline (PBS; pH 7.2) and counted in a
hemocytometer. The viability of the fungal suspensions, determined by staining
with Janus B (Merck, Darmstadt, Germany), was always higher than 90%.
MAbs. The MAbs against gp43—19G, 10D, 32H, and 17D (immunoglobulin
G2a [IgG2a]) and 21F and 3E (IgG2b)—were previously characterized (36). IgG
ascites was generated in BALB/c mice given intraperitoneal (i.p.) injections of
MAb hybridomas. IgG MAbs were purified from ascitic fluid by protein A affinity
chromatography (Pierce, Rockland, IL) as per the manufacturer’s instructions.
Endotoxin (lipopolysaccharide) concentration was 1 ng/ml, measured by the
Limulus amebocyte test (BioWhittaker, Walkersville, MD). The antibody con-
centration was determined by enzyme-linked immunosorbent assay (ELISA)
relative to isotype-matched standards. Irrelevant IgG MAb was used as a control
and was provided by Elaine G. Rodrigues, Universidade Federal de Sa˜o Paulo.
Endotoxin-free preparations. Disposable pyrogen-free plasticware and endo-
toxin-free water or PBS were used in all experiments. Ascitic fluid and isolated
MAb were further purified in Detoxi-Gel columns (Pierce, Rockland, IL) to
remove any endotoxin contamination.
Phagocytosis assay. Peritoneal and alveolar macrophages from BALB/c mice
were harvested by washing the abdominal cavities or the lungs and culturing
adherent cells in Dulbecco’s modified Eagle’s medium with 10% heat-inactivated
fetal calf serum and 1% nonessential amino acids (Cultilab, Brazil). Other
phagocytosis experiments were carried out with the J774.16 macrophage-like cell
line, derived from a reticulum cell sarcoma (37), or with the MH-S line, origi-
nated from an SV40-transformed adherent cell-enriched population of alveolar
macrophages (23). The protocol for in vitro phagocytosis was that described in
earlier studies (46, 47) with minor modifications. Primary cells were plated on
96-well tissue culture plates (Switzerland) at a final density of 1.6 105 cells/well,
and macrophage-like cells were plated at a density of 0.8  105 to 1  105
macrophages in order to obtain the same density after overnight incubation. The
cells were stimulated with 50 U/ml recombinant murine IFN- (PeproTech,
Rock Hill, NJ) and incubated at 37°C overnight. Phagocytosis was measured in
the presence or absence of purified MAbs (0 to 100 g/ml). P. brasiliensis cells
were added at a ratio of 5:1 macrophages to fungal cells and incubated at 37°C
for 6, 12, and 24 h. The cells were then washed several times with sterile PBS,
fixed with cold absolute methanol, and stained with a 1/20 solution of Giemsa
(Sigma, St. Louis, MO). Phagocytosed yeasts were counted by light microscopy
at 400 magnification. The phagocytic index (PI) is defined by the equation PI 
P  F, where P is the percentage of macrophages with internalized yeast and F
is the average number of yeast cells per macrophage. Phagocytosis was confirmed
by transmission electron microscopy that showed the internalization of yeast cells
in macrophages (data not shown). Experiments were carried out in triplicate, and
five to eight different fields were counted.
Intratracheal infection of BALB/c mice. BALB/c mice were inoculated i.t. with
3  105 yeast cells of virulent P. brasiliensis Pb18, grown on Sabouraud agar and
suspended in sterile saline (0.85% NaCl), per animal. Briefly, the mice were
anesthetized i.p. with 200 l of a solution containing 80 mg/kg ketamine and 10
mg/kg of xylazine (both from Unia˜o Quı´mica Farmaceˆutica, Brazil). After ap-
proximately 10 min, their necks were hyperextended, and the tracheas were
exposed at the level of the thyroid and injected with 3  105 yeast cells in PBS
using a 26-gauge needle. The incisions were sutured with 5-0 silk.
Fungal burden in organs of i.t. infected mice. For the fungal burden analysis,
two protocols were utilized: (i) 1 mg of MAbs was administrated i.p. 24 h before
the infections, and the mice were sacrificed 15 and 30 days after i.t. infection, and
(ii) 1 mg of MAbs was administered i.p. 30 days after the infections, and the mice
were sacrificed 45 and 60 days after i.t. infection. The fungal burden was mea-
sured by CFU. Sections of the lungs, livers, and spleens were removed, weighed,
homogenized, and then washed three times with PBS. The corresponding pellets
were resuspended and homogenized, each in 1 ml of PBS. A 100-l sample of
this suspension was plated on solid brain heart infusion medium supplemented
with 4% fetal calf serum (Gibco, NY), 5% spent P. brasiliensis (strain 192)
culture supernatant, 10 IU/ml streptomycin/penicillin (Cultilab, Brazil), and 500
g/ml cycloheximide (Sigma, St. Louis, MO). The petri dishes were incubated at
37°C for at least 10 days, and colonies were counted (1 colony  1 CFU).
Histopathology. The lungs of i.t. infected mice were excised, fixed in 10%
buffered formalin, and embedded in paraffin for sectioning. The sections were
stained with hematoxylin-eosin or silver nitrate and examined microscopically at
25 magnification (Optiphot-2; Nikon, Tokyo, Japan).
Fungal burden in organs of i.v.-infected mice. MAbs 3E and 32H and irrele-
vant MAb were administered (1 mg) i.p. 24 h before i.v. infection with 3  105
yeast cells of virulent P. brasiliensis Pb18. A maintenance dose of 100 g of each
MAb was given every week for a month. The mice were sacrificed 30 days after
infection and the fungal burden measured as described for the i.t. infection.
Cytokine analysis. Sections of the lungs (alternating right and left lungs) were
homogenized in 2 ml of PBS in the presence of protease inhibitors (Complete
Mini; Boehringer Mannheim, Indianapolis, IN). The homogenates were centri-
fuged, and the supernatants frozen at 80°C until tested. The supernatants were
assayed for IL-2, IL-4, IL-10, IL-12, and IFN- using ELISA kits (BD Phar-
Mingen, San Diego, CA). The detection limits of such assays were as follows: 3.1
pg/ml for IL-2, 7.8 pg/ml for IL-4, 31.25 pg/ml for IL-10 and IFN-, and 62.5
pg/ml for IL-12p40, as previously determined by the manufacturer.
Production of nitric oxide. The levels of nitric oxide metabolite (nitrite) were
determined by Griess reaction (33) in the culture supernatant of macrophages
challenged with opsonized yeasts. All determinations were performed in tripli-
cate.
Peptide synthesis and purification for screening. Peptide synthesis and puri-
fication were carried out at the Department of Biophysics, Universidade Federal
de Sa˜o Paulo. The amino acid sequence of P. brasiliensis gp43 glycoprotein
(GenBank accession number AY005437) was used to synthesize the peptides by
solid-phase technology using the 9-fluorenylmethoxy carbonyl strategy on an
automated benchtop simultaneous multiple solid-phase peptide synthesizer
PSSM8 (Shimadzu, Tokyo, Japan) with 9-fluorenylmethoxy carbonyl-protected
amino acid residues and TentaGel Rink resin (Novabiochem, San Diego, CA).
Therefore, all peptides were obtained with the C-terminal carboxyl group in an
amide form. All peptides were deprotected and cleaved from the resins by
treatment with K reagent composed of 80% trifluoroacetic acid, 2.5% triisopro-
pylsilane, 2.5% ethanedithiol, 5.0% anisole, 5.0% water, and 5.0% phenol. The
resulting peptides were analyzed by reverse-phase high-performance liquid chro-
matography (Shimadzu, Tokyo, Japan) on a C18 column eluted at 1 ml/min using
a 5% to 95% gradient of 90% acetonitrile in 0.1% trifluoroacetic acid over 30
min. The peptide quality was assessed by a matrix-assisted laser desorption
ionization–time of flight instrument (Micromass, Manchester, United Kingdom)
using 	-cyano-4-hydroxy cinnamic acid as the matrix.
Peptide containing the reactive epitope of the protective MAb 3H. The peptide
NHVRIPIGYWAV was synthesized at Peptides International (Louisville, KY)
with 95% purity, in both the carboxy and amidated forms.
MAb reactivity with peptides. Antibody reactivity with peptides from gp43 was
determined by ELISA. Microtiter plates coated with 100 ng of each peptide/well
were incubated with 100 l of MAb serially diluted, starting at 10 g/ml, at 37°C
for 1 h. The plates were washed three times and incubated with 100 l of goat
anti-mouse IgG peroxidase (Sigma, St. Louis, MO) for 1 h at 37°C. The plates
were washed, and the reaction was developed with a solution of o-phenylenedi-
amine (0.5 mg/ml; Sigma, St. Louis, MO) and 0.005% H2O2 (Sigma, St. Louis,
MO). The reaction was terminated with 4 N H2SO4 after 8 to 10 min of incu-
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bation in the dark. The optical densities were measured at 492 nm in an ELISA
reader (Titertek Multiskan EIA reader).
Direct effect of MAbs on P. brasiliensis. The growth rate of Pb18 in the
presence of protective and nonprotective MAbs was compared to that in the
presence of irrelevant antibodies or medium alone. Yeast cells were grown in
Sabouraud medium at 37°C, and 100 g/ml of each MAb was added at 96-h
intervals. Culture samples were taken at 48-h intervals, and cell numbers were
counted with a hemocytometer.
Statistical analysis. Statistical analysis was done using GraphPad Prism5 soft-
ware. The results were expressed as the means 
 the standard deviations (SD)
of the indicated numbers of animals or experiments. The nonparametric Tukey’s
honestly significant difference test was used. The unpaired Student’s t test with
Welch’s correction (two-tailed) was used for the comparison of the two groups
when the data met the assumptions of the t tests. P values of 0.05 indicated
statistical significance.
RESULTS
In vitro phagocytosis mediated by MAbs. We investigated
the effect of MAbs to gp43 on P. brasiliensis phagocytosis in
vitro using both primary macrophages (lung and peritoneal)
and cell lines J774.16 and MH-S. Yeast cells opsonized with
MAbs 19G, 21F, 10D, 17D, and 3E were at least twofold more
internalized by J774.16 cells than by nonopsonized or 32H-
opsonized yeast cells (Fig. 1). The same result was obtained
with primary macrophages. The MH-S cell line and the lung
primary macrophages showed similar results. Phagocytosis was
observed regardless of whether or not the macrophages were
activated with IFN-, but the indices were significantly higher
with cytokine-stimulated cells (data not shown).
Yeast cells opsonized with MAbs to gp43 promote macro-
phage fungicidal activity in vitro. MAbs that increase P. bra-
siliensis phagocytosis by macrophages also induce an increase
in nitric oxide metabolite (nitrite) in the supernatants of the
phagocytic cells (Fig. 2).
Passive immunization reduces fungal burden. To evaluate
whether the administration of MAbs could reduce lung CFU
from mice infected with P. brasiliensis, two protocols were
followed. In the first protocol, BALB/c mice were immunized
with different MAbs against gp43 24 h prior to i.t. infection
with 3  105 yeast cells of P. brasiliensis. After 15 days of
infection, the number of CFU in the lungs of mice that received
MAbs 19G, 21F, 10D, 3E, and 17D but not 32H showed a sig-
nificant reduction compared with that of the controls (Fig. 3).
Additionally, MAbs 19G, 10D, and 3E maintained significant
CFU reductions after 30 days of infection (Fig. 3). In the second
protocol, two MAbs were selected, 32H that did not reduce the
lung CFU and 3E that reduced the CFU. BALB/c mice were
infected as indicated above, and after 30 days, 1 mg of MAbs 32H
or 3E was injected i.p. The CFU were measured after 45 and 60
days of infection, and MAb 3E but not 32H was able to reduce the
CFU from the lungs of the mice at day 60 (Fig. 4).
FIG. 1. Phagocytosis of yeast cells by J774.16 cells after 12 h in the
presence of MAbs against gp43 (3E, 10D, 17D, 19G, 21F, and 32H)
compared to that of controls of yeast incubated without MAb (PBS) or
with an irrelevant MAb (MAb A4). Each bar represents the average of
three measurements, and error bars indicate SD. Experiments were
done in triplicate, and different fields were counted. , significant
difference (P  0.05, determined by analysis of variance and Tukey’s
honestly significant difference test) compared to the control without
MAb.
FIG. 2. Nitrite measurements in supernatants from phagocytosis assays. P. brasiliensis yeast was cultured with J774.16 cells for 12 h in the
presence of MAbs against gp43 (3E, 10D, 17D, 19G, 21F, and 32H), PBS (without MAb), or the irrelevant MAb (A4). Nitrite levels were detected
using a Griess assay. , significant difference (P  0.05, determined by analysis of variance and Tukey’s honestly significant difference test) relative
to the PBS control. Error bars denote SD.
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To evaluate the effect of MAbs in mice, an intravenous
infection model was used. Groups of animals were passively
immunized i.p. with 1 mg of MAb 3E, MAb 32H, or the
irrelevant control MAb 24 h prior to infection with 5  106
yeast cells and were given 0.1 mg of the MAbs every week for
1 month before the animals were sacrificed. For the CFU
determinations, the lung, spleen, and liver tissues were homog-
enized separately and plated on solid medium. The mice im-
munized with MAb 3E had significantly lower lung and spleen
CFU compared to the CFU of the mice receiving MAb 32H,
the irrelevant MAb, or PBS (Fig. 5). Liver CFU were below the
detection threshold.
Viability of P. brasiliensis yeast cells in the presence of MAbs
3E and 32H. The viability of yeast cells incubated with MAbs
3E or 32H or the irrelevant MAb was evaluated during 30 days;
no direct inhibitory effects by the MAbs were observed (data
not shown).
Lung histopathology of treated, i.t. infected BALB/c mice
(30 days). The lungs of the untreated control animals showed
intense infiltration, mainly by macrophages, lymphocytes, and
epithelioid cells. Around the foci of the epithelioid granulo-
mas, giant cells were also observed. Multiplying fungal cells
were seen. Using protocol 1 (for which the mice received
MAbs 24 h before i.t. infection), we observed that the animals
FIG. 3. Lung CFU from mice infected i.t. with 3  105 yeast cells and treated with MAbs against gp43 (3E, 10D, 17D, 19G, 21F, and 32H) 24 h
prior to infection. Mice were sacrificed after 15 (black bars) or 30 (gray bars) days of infection. Control mice were infected and received PBS
(infected only) or an irrelevant MAb (A4). Each bar represents the average count of fungi in the lung, and error bars indicate SD. , significant
difference (P  0.05, determined by analysis of variance and Tukey’s honestly significant difference test) relative to the PBS control.
FIG. 4. Lung CFU from mice infected i.t. with 3 105 yeast cells and treated with MAbs against gp43 (3E or 32H) 30 days after infection. Mice
were sacrificed after 45 (black bars) or 60 (gray bars) days of infection. Control mice were infected and received PBS (infected only) or an irrelevant
MAb (A4). Each bar represents the average count of fungi in the lung, and error bars indicate SD. , significant difference (P  0.05) relative to
the PBS control.
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immunized with MAb 32H were pathologically similar to the
infected control mice. In contrast, the animals that received
MAb 3E had fewer epithelioid granulomas with a reduced
number of yeast cells and large areas of preserved lung tissue
(Fig. 6).
MAb treatment alters cytokine expression. Cytokine levels
were detected in the lung tissue of i.t. infected mice treated
with MAb 3E and 32H in both protocols. Groups of 10 mice
were used in each protocol; all experiments were repeated
twice with similar results. As shown in Table 1, with the first
protocol, animals immunized with MAb 3E had higher levels
of IFN- and reduced levels of IL-4 after 15 and 30 days of
infection compared with those of the animals immunized with
MAb 32H. The other cytokines (IL-10, IL-12, and TNF-	)
showed less variability. With the second protocol, the levels of
IL-12 after 45 days of infection and IFN- after 45 and 60 days
of infection were higher than those of MAb 32H (Table 2).
Identification of the epitope of MAb 3E. The reactivity of
MAb 3E was evaluated against a panel of gp43-derived pep-
tides previously described (48). The analysis of the results
suggested that the recognized epitope is within the sequence
NHVRIPIGWAV (data not shown). The MAb 3E but not 32H
recognized this peptide using ELISA (Fig. 7). This peptide
sequence was found to be conserved in the internal sequences
of -1,3-glucanases of Aspergillus fumigatus, Aspergillus oryzae,
and Blumeria graminis.
DISCUSSION
The protective role of antibodies against fungal infections is
in many cases controversial. Recently, several studies have
established that some antibodies are protective against fungi
(31, 41, 52). MAbs or fragments of MAbs have been approved
for the clinical evaluation of cryptococcosis (21) and candidi-
asis (32). Murine MAb 18B7 directed against the capsular
polysaccharide of C. neoformans was used to evaluate the
safety and maximum tolerated dose of a therapeutic MAb. The
study used human immunodeficiency virus-infected patients
who had successfully been treated for cryptococcal meningitis.
The MAb infusion had a half-life in the serum of approxi-
mately 53 h and reduced the fungal circulating antigen (21). In
another study, a human recombinant MAb to heat shock pro-
tein 90 was used in the treatment of patients with invasive
candidiasis (32). A consensus has now emerged that the inabil-
FIG. 5. CFU from lungs (black bars) or spleens (gray bars) of mice infected i.v. with 3  105 yeast cells and treated with 1 mg of MAbs against
gp43 (3E or 32H) 24 h prior to infection and with 100 g every week for a month as a maintenance dose. Mice were sacrificed after 30 days of
infection. Control mice were infected and received PBS (infected only) or an irrelevant MAb (A4). Each bar represents the average count of fungi
in the organ, and error bars indicate SD. , significant difference (P  0.05, determined by analysis of variance and Tukey’s honestly significant
difference test) relative to the PBS control.
FIG. 6. Histopathology of representative lung sections from mice i.t. infected according to protocol 1 and euthanized at 30 days after infection.
(A) Lung section from an untreated infected mouse; (B) lung section from a mouse infected and treated with MAb 32H; (C) lung section from
an infected mouse treated with MAb 3E. Hematoxylin-eosin staining, 10 magnification.
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ity of immune sera to mediate protection against fungi reflects
inadequate amounts of protective antibody and/or the simul-
taneous presence of protective and nonprotective antibodies
rather than a fundamental inability of antibody to protect
against fungal pathogens (11).
The first evidence of an antibody-mediating protection
against P. brasiliensis was described by de Mattos Grosso et al.
(17). The authors showed that the passive transfer of two
murine MAbs against a glycoprotein of 70 kDa, which is rec-
ognized in 96% of the sera from PCM patients, led to a sig-
nificant reduction in the number of CFU in the lungs and fewer
granulomas within the organs of experimentally infected mice
(17). More recently, another MAb that recognizes a secreted
75-kDa protein with phosphatase activity inhibited P. brasilien-
sis growth in vitro and reduced lung CFU in vivo (52).
Although the MAbs to gp43 have not directly affected the
growth of P. brasiliensis, the protective action of the MAbs was
directly associated with their capacity to enhance phagocytosis.
Since macrophages are effector cells capable of exerting yeast
fungicidal effects, we investigated NO production in macro-
phages that had phagocytosed MAb-opsonized yeast cells. The
NO results showed an increase for all “protective” MAbs, but
the response was variable, with MAb 3E demonstrating the
most impressive effect. Previous data from our group and oth-
ers clearly demonstrated that activated macrophages kill the
fungus in vitro by the production of nitric oxide and hydrogen
peroxide (7, 8).
Using a panel of six MAbs against gp43, including IgG2a
(10D, 17D, 19G, and 32H) and IgG2b (3E and 21F), we iden-
tified the protective and nonprotective MAbs by the passive
administration of the antibodies into mice infected i.t. or i.v.
with P. brasiliensis. The presence of protective and nonprotec-
tive antibodies against the same antigen is a conceptually rel-
evant finding that has previously been described for cryptococ-
cosis (27). The histopathology of lung sections from i.t.
infected animals treated with the protective MAb showed a
reduction in the number of yeast cells and epithelioid granu-
lomas in comparison with the untreated control mice.
The role of IFN- in mediating activated macrophages in a
systemic fungal infection has been reported. Murine peritoneal
macrophages activated by IFN- show enhanced fungicidal
activity with both yeast and conidial forms of P. brasiliensis
(7–9). The production of IL-10 has been associated with more
severe disease in susceptible mice (19). Alveolar macrophages
TABLE 1. Protocol 1 cytokine levels in the lungs of mice in response to the passive transfer of MAbs 24 h before i.t.
infection with P. brasiliensis
Cytokine Days ofinfection
Cytokine level (pg/g of tissue)a
Sham Infected only Irrelevant MAb A4 Treated withMAb 3E
Treated with
MAb 32H
IL-4 15 248.2
 63.1 248.7
 43.6 327.1
 56 102.8
 52b 107.7 
 49.1b
30 322.5
 70.7 380.4
 81.9 422.4
 87.8 120.6
 67b 559.5 
 76.9b
IL-10 15 4,204
 269.4 6,786.9
 1,250.1 8,062.5
 926.4 11,027.8
 1,321.8b 12,852 
 1,560b
30 3,920
 330 9,033.3
 978.4 9,357.1
 1,077.8 15,804
 2,135b 24,155 
 1,398b
IL-12 15 4,682.1
 303 8,648.6
 218.2 8,543.7
 743 12,829.9
 1,422.5b 8,724.3 
 1,403.4
30 4,880
 335.8 7,598
 838 7,050
 765 6,535.3
 834.2 10,128.4
 988b
IFN- 15 101 
 13 300 
 35.1 240
 38.3 1,100.8
 115.6b 150.4 
 87.8
30 108 
 10.1 260.9 
 8.3 301.3
 50.8 780
 99.3b 155.7 
 93.4
TNF-	 15 2,142.8
 505 12,616.7
 918.7 11,725
 1,426.6 6,944.4
 1,387.5b 4,217.9 
 657.5b
30 2,680
 622.2 25,794.8
 2,492.2 22,857.1
 2,412 14,456.5
 2,224.4b 11,662.2
 2,380.1b
a Values are means 
 standard deviations of measurements from 10 animals per group. The experiment was repeated twice with reproducible results.
b Statistically significant (P  0.05, determined by analysis of variance and Tukey’s honestly significant difference test) relative to the value for the untreated, infected
mice.
TABLE 2. Protocol 2 cytokine levels in the lungs of mice in response to the passive transfer of MAbs 30 days after i.t.
infection with P. brasiliensis
Cytokine Days ofinfection
Cytokine level (pg/g of tissue)a
Sham Infected only Irrelevant MAb A4 Treated withMAb 3E
Treated with
MAb 32H
IL-4 45 208.2
 73.1 589.2
 81.9 342.3
 36.2 2,151.6
 352b 1,370.6 
 134b
60 254.3
 85.7 862.8
 185.5 764.8
 107.8 1,633.2
 188b 1,832.9 
 287.6b
IL-10 45 1,685.7
 252.5 2,541.9
 172.2 1,666.7
 250 3,245.4
 318.1b 1,790.6 
 240.6b
60 2,360
 494.7 2,760.2
 612.3 3,238.1
 798.4 3,583.3
 279b 2,500 
 839.9
IL-12 45 3,257.6
 370.4 4,912.5
 817.4 8,362.5
 1,969.6 21,337.9
 3,475.9b 12,470.1
 1,815.5b
60 3,243.7
 1,885.6 6,987.4
 891.5 9,509.5
 3,249.4 14,699.3
 2,981.1b 11,630.6
 2,350.8b
IFN- 45 99.41
 33.1 280.9
 41.2 106.6
 29.2 1,328.6
 207.2b 162.5 
 42.1b
60 90.2 
 25.4 382.4
 39.2 133.3
 33 1,229.8
 192.3b 416.4 
 59.3
TNF-	 45 1,980.5
 359 22,870.5
 1,057.6 22,100
 3,225.5 16,985.4
 1,698.2b 18,798.5
 2,785.2b
60 2,010.5
 438.8 30,021
 3,777.8 26,789.2
 1,469.3 14,892.4
 2,001b 21,364.7
 3,911.2b
a Values are means 
 standard deviations of measurements from 10 animals per group. The experiment was repeated twice with reproducible results.
b Statistically significant (P  0.05, determined by analysis of variance and Tukey’s honestly significant difference test) relative to the value for the untreated, infected
mice.
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from i.t. infected IL-4-deficient mice more efficiently control
fungal growth than wild-type macrophages (34), and also IL-
4-deficient mice have increased levels of pulmonary IFN-
(34). The passive administration of irrelevant MAb, 3E, or 32H
in i.t. infected BALB/c mice showed a mixed Th1/Th2 pattern
of activation. Nevertheless, the cytokine changes associated
with protective MAb administration were more Th1-like, given
the increased levels of IFN- and IL-12 in the lungs of i.t.
infected mice. A discreet but statistically significant increase of
IL-10 and a reduction of IL-4 and TNF-	 were noted com-
pared with the levels of IL-10, IL-4, and TNF-	 in the control
infected mice. The passive transfer of MAb 32H induced lower
levels of lung IFN- and IL-12 than MAb 3E treatment. In
fungal disease, the effects of antibody treatment on cytokine
production are poorly understood and may depend on several
features, including the fungus, target organ, timing of fungal
dissemination, and antibody quantity, isotype, and specificity
(18, 39, 49). Antibody-mediated protection has been associated
with lower levels of IFN- in A/J mice infected with C. neo-
formans (18), but both Th1- and Th2-related cytokines are
necessary for antibody protection in cryptococcosis (3). Strong
Th1 responses can result in reduced survival and tissue damage
(22, 39). In our studies, we found that MAb treatment did not
have the polarity of the Th1/Th2 response and that IFN-
appears to be beneficial.
Attempts at determining the epitope of protective MAb 3E
led to the sequence NHVRIPIGYWAV shared with the A.
fumigatus, A. oryzae, and B. graminis internal sequences of
-1,3-glucanases. The opsonizing effect of MAb 3E could then
involve the recognition of this peptide sequence in the gp43
accumulated on the cell wall of P. brasiliensis. In fact, gp43 is
stored inside a vacuole, migrates to the plasma membrane, and
spreads into the P. brasiliensis cell wall. The secretion of this
antigen occurs at discrete sites along the cell surface (45).
Historically, protection against PCM has been attributed to
a vigorous cellular immune response, whereas specific high
levels of antibodies have been associated with disease severity,
as observed in patients with acute and subacute forms. Here we
show that there are protective and nonprotective anti-gp43
antibodies and that the former play an important role in dis-
ease control. Antibodies against gp43 are found in almost
100% of patients with PCM (5). Probably, there is a low con-
centration of protective antibodies in the serum samples of
these patients, and they are not sufficient to control the dis-
ease. To overcome this, passive immunization with MAbs to
gp43 was used and shown to be protective in mouse models of
PCM. The present work also raises the potential therapeutic
use of the peptide carrying the B epitope of MAb 3E in active
immunization adjuvant to chemotherapy and/or in association
with a peptide sequence containing the T-cell epitope of gp43,
known as P10, that elicits a strong cell-mediated immunity and
is protective against experimental infection.
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